Company Profile
Tenax Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- TENX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.93 USD (-1.53%)
Close
Last updated: October 6, 2026
290M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, TENX closed down 1.53% at $1.93. No new same-company headline was identified in the current news window.
Company overview
Cardiopulmonary Drug Developer
Tenax Therapeutics develops therapies for pulmonary hypertension associated with heart failure with preserved ejection fraction. Its lead program repurposes a cardiovascular medicine in an oral formulation for chronic outpatient treatment.
TNX-103 Oral Levosimendan
TNX-103 is an oral formulation of levosimendan, a potassium-channel activator and calcium sensitizer. The drug is intended to improve cardiac and pulmonary vascular function without increasing myocardial oxygen demand.
PH-HFpEF Target Population
The program focuses on patients with pulmonary hypertension caused by HFpEF, a condition associated with exercise limitation, elevated filling pressures, and poor outcomes. No therapy is specifically approved for this population.
LEVEL Phase 3 Program
LEVEL evaluates TNX-103 against placebo using six-minute walk distance and additional cardiopulmonary measures. LEVEL-2 is a second global pivotal study intended to provide confirmatory evidence for regulatory submissions.
Oral Chronic-Treatment Strategy
Levosimendan has been used intravenously in some countries for acute heart failure. Tenax's oral formulation is designed to enable repeat outpatient dosing in a chronic disease setting.
Future catalysts
- Topline results from the Phase 3 LEVEL trial in August 2026.
- Completion of enrollment in the Phase 3 LEVEL-2 trial by the end of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tenax Therapeutics, Inc. (TENX)?
Tenax Therapeutics, Inc. (TENX) most recently closed at 1.93 USD, a -1.53% move versus the previous session.
What is the market cap of Tenax Therapeutics, Inc. (TENX)?
Tenax Therapeutics, Inc. currently has a market capitalization of 290M USD on BioPharmSignal.
What does Tenax Therapeutics, Inc. do?
Cardiopulmonary Drug Developer Tenax Therapeutics develops therapies for pulmonary hypertension associated with heart failure with preserved ejection fraction. Its lead program repurposes a cardiovascular medicine in an oral formulation for chronic outpatient treatment. TNX-103 Oral Levosimendan TNX-103 is an oral formulation of levosimendan, a...
On which exchange is TENX stock listed?
Tenax Therapeutics, Inc. (TENX) is associated with NASDAQ, United States, Biopharma.
What is TNX-103?
TNX-103 Oral Levosimendan TNX-103 is an oral formulation of levosimendan, a potassium-channel activator and calcium sensitizer.
Which conditions is Tenax Therapeutics, Inc. targeting with TNX-103?
Tenax Therapeutics, Inc. is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Tenax Therapeutics, Inc. describe recent progress with TNX-103?
Topline results from the Phase 3 LEVEL trial in August 2026. Completion of enrollment in the Phase 3 LEVEL-2 trial by the end of 2027.
What is LEVEL-2?
LEVEL-2 is a second global pivotal study intended to provide confirmatory evidence for regulatory submissions.